Handling intercurrent events and missing data in non-inferiority trials using the estimand framework: A tuberculosis case study

Author:

Rehal Sunita1ORCID,Cro Suzie2,Phillips Patrick PJ3ORCID,Fielding Katherine4,Carpenter James R45

Affiliation:

1. GlaxoSmithKline, Middlesex, UK

2. Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London, UK

3. UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, CA, USA

4. London School of Hygiene and Tropical Medicine, London, UK

5. Medical Research Council Clinical Trials Unit, University College London, London, UK

Abstract

IntroductionThe ICH E9 addendum outlining the estimand framework for clinical trials was published in 2019 but provides limited guidance around how to handle intercurrent events for non-inferiority studies. Once an estimand is defined, it is also unclear how to deal with missing values using principled analyses for non-inferiority studies.MethodsUsing a tuberculosis clinical trial as a case study, we propose a primary estimand, and an additional estimand suitable for non-inferiority studies. For estimation, multiple imputation methods that align with the estimands for both primary and sensitivity analysis are proposed. We demonstrate estimation methods using the twofold fully conditional specification multiple imputation algorithm and then extend and use reference-based multiple imputation for a binary outcome to target the relevant estimands, proposing sensitivity analyses under each. We compare the results from using these multiple imputation methods with those from the original study.ResultsConsistent with the ICH E9 addendum, estimands can be constructed for a non-inferiority trial which improves on the per-protocol/intention-to-treat-type analysis population previously advocated, involving respectively a hypothetical or treatment policy strategy to handle relevant intercurrent events. Results from using the ‘twofold’ multiple imputation approach to estimate the primary hypothetical estimand, and using reference-based methods for an additional treatment policy estimand, including sensitivity analyses to handle the missing data, were consistent with the original study’s reported per-protocol and intention-to-treat analysis in failing to demonstrate non-inferiority.ConclusionsUsing carefully constructed estimands and appropriate primary and sensitivity estimators, using all the information available, results in a more principled and statistically rigorous approach to analysis. Doing so provides an accurate interpretation of the estimand.

Funder

medical research council

National Institute for Health and Care Research

Medical Research Council Programme

Publisher

SAGE Publications

Subject

Pharmacology,General Medicine

Reference39 articles.

1. European Medicines Agency. ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials, 2020, https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical-principles_en.pdf

2. Reporting of Noninferiority and Equivalence Randomized Trials

3. Reporting of Noninferiority and Equivalence Randomized Trials

4. The European Agency for the Evaluation of Medicinal Products. Points to consider on switching between superiority and non-inferiority, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003658.pdf (2000, accessed 3 November 2015).

5. Food and Drug Administration. Non-inferiority clinical trials to establish effectiveness: guidance for industry, 2016, https://www.fda.gov/media/78504/download

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3